Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression:: Implications for gene therapy

被引:207
作者
Kafri, T
Morgan, D
Krahl, T
Sarvetnick, N
Sherman, L
Verma, I
机构
[1] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA
[2] Scripps Res Inst, La Jolla, CA 92037 USA
关键词
D O I
10.1073/pnas.95.19.11377
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Replication-defective adenoviral (RDAd) vectors can be generated at high titers and infect both dividing and nondividing cells. Long term expression in the transduced tissue, however, has been a problem because of the cellular immune responses against the infected cells. We demonstrate that mice injected with RDAd vectors containing mouse leptin gene reduce food intake and lose weight for only 7 to 10 days. Splenocytes obtained from infected mice are able to lyse target cells infected with RDAd vectors. Surprisingly, target cells infected with psoralen-treated, UV-crosslinked, biologically inactive RDAd also were lysed efficiently by the effector cells, Furthermore, splenocytes obtained from mice injected with inactive RDAd vectors efficiently lysed target cells infected with RDAd vectors, Whether RDAd vectors were injected i.m. or i.v, or through an i.p. route, the extent of lysis was similar. We propose that cel:ls infected with RDAd vectors present antigens for recognition by class 1 major histocompatibility complex-restricted cytotoxic T lymphocytes by a mechanism that does not require viral replication or de novo protein synthesis, These results should prompt reevaluation of the use of RDAd vectors for gene therapy when long-term expression is required.
引用
收藏
页码:11377 / 11382
页数:6
相关论文
共 42 条
[11]   STEPWISE DISMANTLING OF ADENOVIRUS-2 DURING ENTRY INTO CELLS [J].
GREBER, UF ;
WILLETTS, M ;
WEBSTER, P ;
HELENIUS, A .
CELL, 1993, 75 (03) :477-486
[12]   In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes [J].
Haecker, SE ;
Stedman, HH ;
BaliceGordon, RJ ;
Smith, DBJ ;
Greelish, JP ;
Mitchell, MA ;
Wells, A ;
Sweeney, HL ;
Wilson, JM .
HUMAN GENE THERAPY, 1996, 7 (15) :1907-1914
[13]   Class I MHC presentation of exogenous antigens [J].
Harding, CV .
JOURNAL OF CLINICAL IMMUNOLOGY, 1996, 16 (02) :90-96
[14]   Construction of adenovirus vectors through Cre-lox recombination [J].
Hardy, S ;
Kitamura, M ;
HarrisStansil, T ;
Dai, YM ;
Phipps, ML .
JOURNAL OF VIROLOGY, 1997, 71 (03) :1842-1849
[15]   Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors [J].
Kafri, T ;
Blomer, U ;
Peterson, DA ;
Gage, FH ;
Verma, IM .
NATURE GENETICS, 1997, 17 (03) :314-317
[16]   EFFICIENT GENE ACTIVATION IN MAMMALIAN-CELLS BY USING RECOMBINANT ADENOVIRUS EXPRESSING SITE-SPECIFIC CRE RECOMBINASE [J].
KANEGAE, Y ;
LEE, G ;
SATO, Y ;
TANAKA, M ;
NAKAI, M ;
SAKAKI, T ;
SUGANO, S ;
SAITO, I .
NUCLEIC ACIDS RESEARCH, 1995, 23 (19) :3816-3821
[17]   IN-VIVO HEPATIC GENE-THERAPY - COMPLETE ALBEIT TRANSIENT CORRECTION OF FACTOR-IX DEFICIENCY IN HEMOPHILIA-B DOGS [J].
KAY, MA ;
LANDEN, CN ;
ROTHENBERG, SR ;
TAYLOR, LA ;
LELAND, F ;
WIEHLE, S ;
FANG, BL ;
BELLINGER, D ;
FINEGOLD, M ;
THOMPSON, AR ;
READ, M ;
BRINKHOUS, KM ;
WOO, SLC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2353-2357
[18]   LONG-TERM HEPATIC ADENOVIRUS-MEDIATED GENE-EXPRESSION IN MICE FOLLOWING CTLA4LG ADMINISTRATION [J].
KAY, MA ;
HOLTERMAN, AX ;
MEUSE, L ;
GOWN, A ;
OCHS, HD ;
LINSLEY, PS ;
WILSON, CB .
NATURE GENETICS, 1995, 11 (02) :191-197
[19]   A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase [J].
Kochanek, S ;
Clemens, PR ;
Mitani, K ;
Chen, HH ;
Chan, S ;
Caskey, CT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) :5731-5736
[20]   GENE-THERAPY - ADENOVIRUS VECTORS [J].
KOZARSKY, KF ;
WILSON, JM .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1993, 3 (03) :499-503